FluoGuide A/S ("FluoGuide" or "the Company") hereby announce that due to dilution in connection to the warrant exercise for warrants of series TO 1, that was fully exercised, Wexotec ApS, which is CEO Morten Albrechtsen’s fully owned company that owns 1,487,394 shares in FluoGuide, passes the 15 percent limit. Wecotec ApS shareholdings goes from approx. 15.7 percent of the shares in the Company to owning approx. 14.1 percent. 

For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is planning a proof-of-concept clinical study (phase I/IIa) to demonstrate the effect of FG001 in patients with glioblastoma.